跳转至内容
Merck
所有图片(1)

主要文件

20030-U

Supelco

ORBO 活性硅胶管

W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea

别名:

ORBO Activated Silica Gel Tube

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12190000
NACRES:
NB.24

材料

W,W,F separators
silica gel

品質等級

agency

NIOSH 2000,5518

產品線

ORBO

成份

Bed A, 100 mg
Bed B, 50 mg

包裝

pkg of 50 ea

製造商/商標名

ORBO 502

技術

active air sampling: suitable

外徑 × 長度

6 mm × 75 mm

基質

activated silica gel

粒徑

20-45 mesh

應用

air monitoring
environmental
industrial hygiene

正在寻找类似产品? 访问 产品对比指南

一般說明

ORBO 502 Activated Silica Gel (20/45) 100/50 mg sorbent tubes (W,W,F separators, O.D. × L 6 mm × 75 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

法律資訊

ORBO is a trademark of Sigma-Aldrich Co. LLC

未找到合适的产品?  

试试我们的产品选型工具.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Anne Beate Vereide et al.
Gynecologic oncology, 97(3), 740-750 (2005-05-12)
The aim of the study was to investigate apoptosis as a growth regulatory mechanism of gestagen in endometrial precancers and to compare differences in the apoptotic cascade after high and low dose gestagen regimens. Pre- and post-treatment paraffin-embedded endometrial hyperplasia
A Orbo et al.
Gynecologic oncology, 95(1), 82-88 (2004-09-24)
The purpose of the current study was to characterize the role of PTEN in malignant transformation and to evaluate the significance of mutated PTEN exons as prognostic markers in the carcinogenesis of endometrial hyperplasia. A comparison of PTEN mutations as
A Ørbo et al.
BJOG : an international journal of obstetrics and gynaecology, 123(9), 1512-1519 (2015-12-03)
To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response. A multicentre
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门